17.15- 20.30 (Programme Details Below)

Dr. Jeffrey Stavenhagen, VP Biology Therachon

Title: Building a Successful Biotech for Developing Innovative Therapies for Rare Diseases such as Paediatric Achondroplasia (Short Limbed Dwarfism)

Dr. Stavenhagen is an established biotech executive and industry leader in development of novel biologics, and currently holds the position as Vice President Biology at Therachon with responsibility for all research and CMC activities.

Prior to joining Therachon he was the first Global Head of Biologics at H. Lundbeck A/S, Copenhagen where he oversaw the discovery and development of antibody therapies for the treatment of neurodegenerative diseases for over seven years. He was also the first employee at MacroGenics, where he held positions of increasing responsibility. He is an inventor of Margetuximab, which has recently Please register using the following link: https://tias2019.sciforum.net/ completed a successful phase 3 trial in metastatic breast cancer. Dr.Stavenhagen received his PhD from Columbia University, New York and undertook post-doctoral research at the Fred Hutchinson Cancer Research Center, Seattle.

About Therachon

Therachon is a privately held clinical-stage global biotechnology company focused on the discovery and development of innovative treatments for severe, rare diseases with significant unmet need. The company is currently advancing a pipeline of therapeutics focused on rare musculoskeletal disorders and conditions, including both achondroplasia, a genetic condition which is the most common form of short limbed dwarfism, and gastrointestinal disorders such as short bowel syndrome (SBS). Therachon is committed to making a difference in the lives of patients living with serious rare conditions.

About Pfizer’s Acquisition of Therachon

Pfizer has entered into a definitive agreement to acquire all the shares of Therachon Holding AG. Under the terms of the agreement, Pfizer will acquire Therachon for $340 million upfront with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46 for the treatment of achondroplasia, which can result in serious cardiovascular, neurological and metabolic complications for approximately 250,000 children and adolescents worldwide. There are currently no approved treatments for achondroplasia. TA-46 is an investigational, soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy, a mechanism of action that is believed to normalize the overactive FGFR3 signaling pathways that underlie bone development abnormalities associated with achondroplasia. Therachon is developing TA- 46 as a weekly subcutaneous injection for children and adolescents living with the condition. TA-46 has completed Phase 1 and has received Orphan Drug Designation from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Dr. Michael Altorfer, CEO, Swiss Biotech Association

Title: Switzerland's Soaring Biotech Hub and Powerful Source of Global Innovation

Dr Altorfer has more than 20 years of experience in the life science industry in both big pharma and smaller biotech companies. He has been CEO of the Swiss Biotechnology Association since October 2017, and immediately prior he was CEO of Polyphor Ltd, Allschwil, having been previously a member of the Executive Committee in various roles (Head BD&L, CFO, and COO) within the company. From 1996 to 2001 he also worked for investment bank UBS Warburg in programme and line management roles.

His early career as a scientist in pharmaceutical research included Sandoz, Ciba-Geigy, and Roche, after studying natural sciences at ETH and then achieving a Chemistry PhD with supervision from Prof. Dr. H J Hansen (University of Zurich) and Prof Dr K Müller (Roche). He also holds an MBA degree from University of Rochester, NY.

Bajoe Wibowo, Project Manager, Office of Deputy Director General Development Sector,
World Intellectual Property Organization (WIPO), Geneva

Title: Benefits of WIPO Match Platform for Public-Private Partnership (PPP)
Projects in Developing Countries & Countries in Transition in Life Sciences, Biotech and Pharmaceutical Sectors

Mr. Bajoe Wibowo, a national of Indonesia, has been working for more than 20 years at WIPO, and has represented WIPO as a speaker in more than 75 countries. He has handled many specialist assignments, dealing with issues related to the Patent Cooperation Treaty (PCT), Patent information, Intellectual Property (IP) ,and Economic Development, and was involved in the political process of the WIPO Development Agenda.

Presently he is Project Manager in the Office of the Deputy Director General, Development Sector, with special responsibility to manage the WIPO Match Platform – an online tool to match seekers of specific IP-related development needs with potential providers offering resources.

This service amplifies WIPO’s resources and multiplies existing partnerships. WIPO Match is not only a platform for technical assistance projects, but also a platform that can bring new business opportunities for more sophisticated integrated IP and innovation projects (e.g. Private Public Partnership (PPP), and South-South Cooperation projects.

Mr. Wibowo holds a Master’s Degree in Engineering and also a Master’s Degree in Management from Ecole Polytechnique Fédérale de Lausanne (www.epfl.ch).

Where: Biozentrum, University of Basel, Klingelbergstrasse 70, 4056 Basel